The massive potential dilution (~97% of current float) and disclosed going concern risk are the dominant signals. The stock trades at $28.62 vs the $11.00 warrant strike, giving selling stockholders a massive incentive to sell. Monitor for selling pressure as the registration becomes effective. The company's cash runway and ability to avoid further dilutive financing are key watchpoints.
Price Chart
Executive Summary
Cue Biopharma filed an S-3 registration statement to register 4,090,908 shares of common stock for resale by selling stockholders, consisting of shares issuable upon exercise of pre-funded warrants (2,727,272 shares) and warrants (1,363,636 shares) issued in a private placement that closed on May 4, 2026. The company received gross proceeds of approximately $30.0 million from the private placement and will not receive any proceeds from the resale of shares, except from any cash exercise of the warrants at $11.00 per share. The filing is a routine contractual obligation to register the shares for resale, but it highlights the company's going concern risk and need for additional capital as disclosed in the prospectus.
Key Facts
- S-3 registers 4,090,908 shares for resale by selling stockholders from a private placement that closed May 4, 2026
- Company received ~$30.0M gross proceeds (~$28.0M net) from the private placement
- Pre-funded warrants have $0.001 exercise price; warrants have $11.00 exercise price and 5-year term
- As of June 1, 2026, the company had 4,200,343 shares outstanding; the registered shares represent ~97% dilution relative to current outstanding
- Prospectus discloses 'substantial doubt regarding our ability to continue as a going concern' and recurring operating losses
- Company is a clinical-stage biopharma with no commercial revenue or FDA-approved products
- Stock closed at $28.62 on June 2, 2026, well above the $11.00 warrant exercise price, creating significant overhang
Financial Impact
Potential dilution of ~97% if all 4,090,908 registered shares are issued and sold, relative to 4,200,343 shares outstanding. The company received $30M gross proceeds already; warrant cash exercises could add up to ~$15M more at $11.00/share.
Risk Factors
- Massive dilution from potential exercise and resale of 4.09M shares (~97% of current outstanding)
- Going concern risk disclosed in prospectus — company has recurring losses and no commercial revenue
- Selling stockholders have strong incentive to sell given $28.62 stock price vs $11.00 warrant strike
- Clinical-stage biotech with no approved products and need for substantial additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-255418 |
| Document: d103205dexfilingfees.htm | 0001193125-26-255418 |
| Document: d103205dex51.htm | 0001193125-26-255418 |
| Document: d103205dex231.htm | 0001193125-26-255418 |
| Document: 0001193125-26-255418-index-headers.html | 0001193125-26-255418 |
| Document: 0001193125-26-255418-index.html | 0001193125-26-255418 |
| Document: 0001193125-26-255418.txt | 0001193125-26-255418 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers